Atlas Trials

A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization

Clinical trial NCT06503250 · COMPLETED

Trial details

NCT number
NCT06503250
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Study type
OBSERVATIONAL
Unresectable Hepatocellular Carcinoma
Start date
2024-07-19
Primary completion
2024-11-27
Enrollment
113

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.